SPOTLIGHT -
Unmet Needs and Clinical Pearls in mCRPC
Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.
The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC
Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.
Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel
Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.
Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial
Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.
Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials
Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer
Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.
The Future of Prostate Cancer Imaging
Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.
Prostate Cancer Imaging: the VISION Trial
Neal Shore, MD, FACS, reviews the VISION clinical trial in prostate cancer imaging.
Patient Profile 7: Gleason 7 Prostate Cancer
A look at the patient profile of a 62-year-old man presenting with reduced urinary flow and hematuria.
Current Challenges and Future Directions in Metastatic Prostate Cancer
Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.
Potential Use of PARP Inhibitors for First-Line Treatment of mCRPC
A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.
A Urologist’s Treatment Selection for Metastatic Prostate Cancer
Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.
Olaparib Safety and Efficacy Data from the PROfound Trial
An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.
Available Treatment Options for Chemotherapy-Naïve mCRPC
Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
Mutations in HRR-Related Genes in Prostate Cancer
A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.
The Utility of Genetic Testing in Patients with Prostate Cancer
An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.
Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression
Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.
Case Presentation: A 64-Year-Old Man with Metastatic Prostate Cancer
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.
Patient Profile 6: Robotic Radical Prostatectomy for Adenocarcinoma
Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.
Patient Profile 5: IMRT for Adenocarcinoma
Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.
Prostate Cancer Imaging: the CONDOR Trial
Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.
Patient Profile 4: Recurrent Prostate Cancer
Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.
Bone Scans for Prostate Cancer Imaging
A panel of experts review whether bone scans still have a place in prostate cancer imaging.
Patient Profile 3: High-Risk Prostate Cancer
Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.
Patient Profile 2: High-Risk Prostate Cancer
Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.
The Role for PSMA PET Imaging in Prostate Cancer Monitoring
A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.
Discussing Treatments with Patients Based on Prostate Cancer Imaging
A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.
Visual Analysis vs SUV for Prostate Cancer Imaging
Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.